Spisso K R, Harbert G M, Thiagarajah S
Am J Obstet Gynecol. 1982 Apr 1;142(7):840-5. doi: 10.1016/s0002-9378(16)32529-7.
The efficacy of magnesium sulfate was evaluated as the primary tocolytic agent in the management of patients at risk for premature delivery. One hundred ninety-two patients determined to be 36 weeks' gestation or less were treated. One hundred seven patients (55.7%) received an additional oral beta-mimetic agent once labor was arrested. One hundred nineteen patients had intact membranes and 73 patients had ruptured membranes. Delay of delivery of 48 hours or longer was achieved in 70.6% of the patients with intact membranes and 60.2% of patients with ruptured membranes. Intervening obstetric complications, maternal morbidity, and neonatal septic and respiratory morbidity were increased in patients with ruptured membranes compared to patients with intact membranes. Magnesium sulfate is considered to be effective tocolytic agent having minimal adverse effects in managing patients at risk for premature delivery. Its use in patients with ruptured membranes, as with any tocolytic agent, remains controversial.
硫酸镁作为治疗早产风险患者的主要宫缩抑制剂的疗效进行了评估。对192例妊娠36周及以下的患者进行了治疗。一旦宫缩停止，107例患者（55.7%）额外接受了口服β-拟交感神经药物治疗。119例患者胎膜完整，73例患者胎膜已破。胎膜完整的患者中有70.6%实现了48小时或更长时间的分娩延迟，胎膜已破的患者中有60.2%实现了这一点。与胎膜完整的患者相比，胎膜已破的患者产科并发症、孕产妇发病率以及新生儿败血症和呼吸道发病率均有所增加。硫酸镁被认为是一种有效的宫缩抑制剂，在治疗早产风险患者时副作用最小。与任何宫缩抑制剂一样，其在胎膜已破患者中的使用仍存在争议。
